Researchers in the UAE have leveraged artificial intelligence to discover a new class of drug candidates that could potentially treat certain blood cancers, marking another major milestone in the country’s rapidly expanding biotechnology sector.
AI Speeds Up Search for New Cancer Treatments
The breakthrough comes from Insilico Medicine, a clinical-stage biotechnology company operating from Masdar City in Abu Dhabi. Scientists used advanced AI platforms to identify and design compounds capable of targeting proteins linked to blood cancers such as leukemia and lymphoma.
According to Emirati chemist Ahmad Alghaith, AI has the potential to increase the success rate of drug discovery while significantly reducing the time and cost associated with pharmaceutical research.
From Years to Months
Traditional drug discovery can take between two-and-a-half and four years before researchers identify a candidate suitable for further testing. By contrast, Insilico Medicine’s AI-driven process can reduce that timeline to just 12 to 18 months.
The company relies on its proprietary AI platforms, PandaOmics and Chemistry42, to identify disease-related proteins and generate molecular designs that could become future medicines.
A Different Way to Fight Cancer
The newly discovered compounds belong to a category known as PROTACs, which work differently from conventional drugs. Instead of simply blocking harmful proteins, they direct the body’s natural cellular disposal system to eliminate them altogether.
Researchers targeted Bruton’s Tyrosine Kinase (BTK), a protein that helps malignant blood cancer cells grow and survive. The approach could offer new options for patients suffering from certain forms of leukemia and lymphoma.
A Growing Innovation Hub
The findings, published in the Journal of Medicinal Chemistry, further strengthen the UAE’s reputation as a regional centre for scientific research and AI-driven healthcare innovation.
This is the latest in a series of AI-assisted discoveries announced by Insilico Medicine in 2026, following potential treatments for brain cancer and chronic pain developed by its Abu Dhabi-based research team.
What’s Next?
While the discovery is promising, the compounds remain in the preclinical stage and will require further testing, regulatory approvals and human clinical trials before they can potentially reach patients.
As AI continues to transform healthcare, the UAE’s latest breakthrough demonstrates how emerging technologies could help bring life-saving treatments to market faster and more efficiently than ever before.
